AR100712A1 - Compuestos de pirazol como bloqueadores de los canales de calcio tipo t - Google Patents
Compuestos de pirazol como bloqueadores de los canales de calcio tipo tInfo
- Publication number
- AR100712A1 AR100712A1 ARP150101743A ARP150101743A AR100712A1 AR 100712 A1 AR100712 A1 AR 100712A1 AR P150101743 A ARP150101743 A AR P150101743A AR P150101743 A ARP150101743 A AR P150101743A AR 100712 A1 AR100712 A1 AR 100712A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- fluoroalkyl
- cyano
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos son útiles como bloqueadores de los canales de calcio tipo T. Reivindicación 1: Un compuesto de fórmula (1) en donde X representa un átomo de carbono anular o de nitrógeno anular; R¹ representa alquilo C₂₋₆; alquilo C₂₋₄ monosustituido con ciano o alcoxi C₁₋₃; fluoroalquilo C₁₋₄; fluoroalcoxi C₁₋₃; pentafluoro-sulfanilo; cicloalquilo C₃₋₆-L¹- en donde dicho cicloalquilo C₃₋₆ opcionalmente contiene un átomo de oxígeno anular; en donde dicho cicloalquilo C₃₋₆ no está sustituido o está monosustituido con flúor, alquilo C₁₋₃, alcoxi C₁₋₃, hidroxi, ciano o fluoroalquilo C₁₋₃ o disustituido con flúor o trisustituido con dos sustituyentes flúor y un sustituyente seleccionado entre alquilo C₁₋₃ y ciano; y el conector L¹ representa un enlace directo, alquileno C₁₋₂, oxígeno o alquilen C₁₋₂-oxi; heteroarilo de 5 ó 6 miembros, de manera independiente opcionalmente monosustituido con alquilo C₁₋₃; -NR¹¹R¹², en donde R¹¹ y R¹² independientemente representan hidrógeno, alquilo C₁₋₃, fluoroalquilo C₂₋₃, cicloalquilo C₃₋₆, cicloalquilo C₃₋₆ monosustituido o disustituido con flúor, cicloalquil C₃₋₆-alquilo C₁₋₃, alcoxi C₁₋₃-alquilo C₂₋₃; o R¹¹ y R¹², junto con el átomo de nitrógeno al cual están unidos, forman un anillo de 4 a 6 miembros opcionalmente monosustituido o disustituido con flúor; un grupo 2-oxo-pirrolidinilo o un grupo morfolinilo; y (R⁴)ₙ representa uno o dos sustituyentes opcionales independientemente seleccionados entre alquilo C₁₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₄, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃, halógeno y ciano; o R¹ junto con (R⁴)ₙ forman un anillo no aromático de 5 ó 6 miembros que está fusionado al anillo fenilo / piridina; en donde dicho anillo de 5 ó 6 miembros opcionalmente contiene uno o dos heteroátomos seleccionados independientemente entre oxígeno y nitrógeno; en donde dicho anillo no aromático de 5 ó 6 miembros fusionado está, de manera independiente, a su vez opcionalmente monosustituido con oxo o alquilo C₁₋₃; disustituido con alquilo C₁₋₃; o di-, tri- o tetra-sustituido en donde un sustituyente es oxo y los demás son alquilo C₁₋₃; o R¹ junto con (R⁴)ₙ forman un anillo aromático de 5 ó 6 miembros que está fusionado al anillo fenilo / piridina; en donde dicho anillo de 5 ó 6 miembros opcionalmente contiene uno o dos heteroátomos seleccionados de nitrógeno, en donde dicho anillo aromático de 5 ó 6 miembros fusionado está, de manera independiente, a su vez opcionalmente monosustituido o disustituido en donde los sustituyentes se seleccionan de manera independiente entre alquilo C₁₋₃, cicloalquilo C₃₋₆, fluoroalquilo C₁ o ciano; o R¹ representa metilo o halógeno; y (R⁴)ₙ representa un sustituyente seleccionado de fluoroalcoxi C₁₋₃ que está unido al anillo fenilo / piridinilo en la posición orto o meta por el punto de unión del grupo -CH₂-CO-NH-; Y representa un átomo de carbono anular o de nitrógeno anular; y R² representa alquilo C₁₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₄, cicloalquil C₃₋₆-oxi, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃, alcoxi C₁₋₃-alcoxi C₂₋₃, halógeno, ciano, o -NR²¹R²², en donde R²¹ y R²² independientemente representan hidrógeno o alquilo C₁₋₃, o R²¹ y R²², junto con el átomo de nitrógeno al cual están unidos, forman un anillo de 4 a 6 miembros opcionalmente monosustituido o disustituido con flúor o un grupo morfolinilo; y (R⁵)ₘ representa uno o dos sustituyentes opcionales independientemente seleccionados entre alquilo C₁₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₄, halógeno, ciano, fluoroalquilo C₁₋₃ y fluoroalcoxi C₁₋₃; o una sal de dicho compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2014061901 | 2014-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100712A1 true AR100712A1 (es) | 2016-10-26 |
Family
ID=53385705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101743A AR100712A1 (es) | 2014-06-03 | 2015-06-02 | Compuestos de pirazol como bloqueadores de los canales de calcio tipo t |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US9932314B2 (es) |
| EP (1) | EP3152199B1 (es) |
| JP (1) | JP6195684B2 (es) |
| KR (1) | KR101906031B1 (es) |
| CN (1) | CN106414429B (es) |
| AR (1) | AR100712A1 (es) |
| AU (1) | AU2015270118C1 (es) |
| CA (1) | CA2947002C (es) |
| CL (1) | CL2016003092A1 (es) |
| CY (1) | CY1120864T1 (es) |
| DK (1) | DK3152199T3 (es) |
| EA (1) | EA031104B1 (es) |
| ES (1) | ES2696351T3 (es) |
| HR (1) | HRP20181670T1 (es) |
| HU (1) | HUE040489T2 (es) |
| IL (1) | IL249275B (es) |
| LT (1) | LT3152199T (es) |
| MA (1) | MA40281B1 (es) |
| MX (1) | MX2016015923A (es) |
| NZ (1) | NZ727818A (es) |
| PE (1) | PE20170129A1 (es) |
| PH (1) | PH12016502230A1 (es) |
| PL (1) | PL3152199T3 (es) |
| PT (1) | PT3152199T (es) |
| RS (1) | RS57943B1 (es) |
| SG (1) | SG11201609974PA (es) |
| SI (1) | SI3152199T1 (es) |
| TN (1) | TN2016000542A1 (es) |
| TR (1) | TR201816624T4 (es) |
| TW (2) | TWI675827B (es) |
| UA (1) | UA121548C2 (es) |
| WO (1) | WO2015186056A1 (es) |
| ZA (1) | ZA201608821B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3152199T1 (sl) | 2014-06-03 | 2018-12-31 | Idorsia Pharmaceuticals Ltd | Pirazolne spojine in njihova uporaba kot blokatorji kalcijevega kanala tipa T |
| US10246426B2 (en) | 2014-09-15 | 2019-04-02 | Idorsia Pharmaceuticals Ltd | Triazole compounds as T-type calcium channel blockers |
| KR102486298B1 (ko) * | 2016-02-09 | 2023-01-06 | 인벤티스바이오 엘엘씨 | 인돌아민-2,3-디옥시게나아제(ido)의 억제제 |
| US11046683B2 (en) | 2016-12-15 | 2021-06-29 | Ono Pharmaceutical Co., Ltd. | Activator of TREK (TWIK RElated K+ channels) channels |
| KR102296653B1 (ko) * | 2016-12-16 | 2021-09-01 | 이도르시아 파마슈티컬스 리미티드 | T-유형 칼슘 채널 차단제를 포함하는 약학 조합물 |
| US20210128537A1 (en) * | 2016-12-21 | 2021-05-06 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
| TWI808960B (zh) * | 2017-02-06 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 用於合成1-芳基-1-三氟甲基環丙烷之新穎方法 |
| AU2018296423B2 (en) * | 2017-07-05 | 2022-07-28 | Idorsia Pharmaceuticals Ltd | Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
| US11795148B2 (en) | 2017-12-12 | 2023-10-24 | Queen's University At Kingston | Compounds and methods for inhibiting CYP26 enzymes |
| EP3997068A1 (en) | 2019-07-11 | 2022-05-18 | Cura Therapeutics, LLC | Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases |
| JP2022540253A (ja) | 2019-07-11 | 2022-09-14 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｔ型カルシウムチャネル調節因子の製剤およびその使用方法 |
| EP4076405A1 (en) | 2019-12-20 | 2022-10-26 | Idorsia Pharmaceuticals Ltd | Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
| WO2023277658A1 (ko) * | 2021-07-02 | 2023-01-05 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
| WO2023240205A1 (en) | 2022-06-10 | 2023-12-14 | Neurocrine Biosciences, Inc. | Deuterated compounds |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69526790T2 (de) | 1994-06-24 | 2003-03-06 | Euroceltique S.A., Luxemburg/Luxembourg | Verbindungen zur hemmung von phosphodiesrerase iv |
| CN1246847A (zh) | 1996-12-23 | 2000-03-08 | 杜邦药品公司 | 作为Xa因子抑制剂的含氮杂芳族化合物 |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| EP1359911A2 (en) | 2000-12-29 | 2003-11-12 | Alteon, Inc. | Method for treating fibrotic diseases or other indications ivc |
| EP1353674A1 (en) | 2000-12-29 | 2003-10-22 | Alteon, Inc. | Method for treating glaucoma ivb |
| ATE455104T1 (de) | 2001-11-01 | 2010-01-15 | Icagen Inc | Pyrazolamide zur anwendung in der behandlung von schmerz |
| ES2295441T3 (es) | 2001-12-18 | 2008-04-16 | MERCK & CO., INC. | Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato. |
| DE60222698T2 (de) | 2001-12-18 | 2008-06-19 | Merck & Co., Inc. | Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5 |
| SE0201658D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
| CN100387594C (zh) | 2003-04-03 | 2008-05-14 | 麦克公司 | 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂 |
| CA2521396A1 (en) | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| EP1620405A2 (en) * | 2003-05-01 | 2006-02-01 | Abbott Laboratories | Pyrazole-amides and sulfonamides as sodium channel modulators |
| GB0328796D0 (en) | 2003-12-12 | 2004-01-14 | Biofocus Plc | Compounds which interact with the G-protein coupled receptor family |
| SI1781662T1 (sl) | 2004-08-18 | 2011-07-29 | Pfizer | Zaviralci RNA-odvisne RNA-polimeraze hepatitisa C in sestavki in zdravljenja, v katerih se uporabljajo |
| MX2007007830A (es) | 2004-12-23 | 2007-07-25 | Glaxo Group Ltd | Compuestos de piridina para el tratamiento de enfermedades mediadas por prostaglandina. |
| GB0508472D0 (en) * | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| GB0508463D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| FR2889234B1 (fr) * | 2005-07-27 | 2007-11-23 | Andre Prieur | Arret de porte a positions de maintien indeterminees |
| KR100654328B1 (ko) * | 2005-08-26 | 2006-12-08 | 한국과학기술연구원 | 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법 |
| US20070197523A1 (en) | 2005-12-22 | 2007-08-23 | Icagen, Inc. | Calcium channel antagonists |
| CN101466676B (zh) * | 2006-04-12 | 2012-07-18 | 默沙东公司 | 吡啶基酰胺类t-型钙通道拮抗剂 |
| EP2261216A3 (en) | 2006-07-24 | 2011-12-14 | F. Hoffmann-La Roche AG | Pyrazoles as glucokinase activators |
| US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
| US20110038850A1 (en) | 2007-01-05 | 2011-02-17 | Didier Bagnol | G Protein-Coupled Receptor and Modulators Thereof For The Treatment of Gaba-Related Neurological Disorders Including Sleep-Related Disorders |
| WO2008156726A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Inhibitors of janus kinases |
| US8501955B2 (en) * | 2007-10-08 | 2013-08-06 | Advinus Therapeutics Private Limited | Acetamide derivatives as glucokinase activators, their process and medicinal application |
| EP2212293A4 (en) | 2007-10-24 | 2010-12-01 | Merck Sharp & Dohme | ANTAGONISTS OF T-TYPE CALCIUM CHANNELS BASED ON HETEROCYCLIC AMIDE |
| US8637513B2 (en) | 2007-10-24 | 2014-01-28 | Merck Sharp & Dohme Corp. | Heterocycle phenyl amide T-type calcium channel antagonists |
| JP2011500807A (ja) | 2007-10-24 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | ピラジニルアミドｔ型カルシウムチャネルアンタゴニスト |
| WO2009118596A2 (en) | 2008-03-26 | 2009-10-01 | Glenmark Pharmaceuticals, S. A. | Phthalimide derivatives as trpa1 modulators |
| AU2009231258A1 (en) | 2008-04-04 | 2009-10-08 | Biomarin Iga Limited | Compounds for treating muscular dystrophy |
| WO2010004390A1 (en) | 2008-06-17 | 2010-01-14 | Glenmark Pharmaceuticals, S.A. | Quinazoline dione derivatives as trpa1 modulators |
| KR101052065B1 (ko) * | 2008-10-15 | 2011-07-27 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법 |
| JP2012513409A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
| WO2010073011A2 (en) | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
| EP2393811A1 (en) | 2009-02-04 | 2011-12-14 | Pfizer Inc. | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives |
| WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| UY32571A (es) * | 2009-04-24 | 2010-11-30 | Glaxo Group Ltd | Compuestos derivados de pirazol amida |
| CA2763821A1 (en) | 2009-06-04 | 2010-12-09 | Novartis Ag | 1h-imidazo[4,5-c]quinolinone derivatives |
| WO2011022315A1 (en) | 2009-08-19 | 2011-02-24 | Merck Sharp & Dohme Corp. | Pyrazinyl phenyl amide t-type calcium channel antagonists |
| US8993612B2 (en) * | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) * | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| WO2011053542A1 (en) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Heterocycle amide t-type calcium channel antagonists |
| CA2782885A1 (en) | 2009-12-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| EP2530078A1 (en) | 2010-01-27 | 2012-12-05 | Takeda Pharmaceutical Company Limited | Thiazole derivative |
| EP2402327B1 (en) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Acetamide compounds as glucokinase activators, their process and medicinal applications |
| JP5862669B2 (ja) | 2010-08-26 | 2016-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のオキサジアゾール阻害剤 |
| KR20120063283A (ko) | 2010-12-07 | 2012-06-15 | 제일약품주식회사 | 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| KR101593288B1 (ko) | 2011-03-07 | 2016-02-11 | 화이자 인코포레이티드 | 항균제로서 유용한 플루오로-피리디논 유도체 |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| UY34200A (es) | 2011-07-21 | 2013-02-28 | Bayer Ip Gmbh | 3-(fluorovinil)pirazoles y su uso |
| US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9868748B2 (en) * | 2013-05-01 | 2018-01-16 | Vitae Pharmaceuticals, Inc. | Thiazolopyrrolidine inhibitors of ROR- γ |
| AR096393A1 (es) | 2013-05-23 | 2015-12-30 | Bayer Cropscience Ag | Compuestos heterocíclicos pesticidas |
| EP2848615A1 (en) * | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
| KR101685993B1 (ko) | 2014-05-15 | 2016-12-13 | 한국과학기술연구원 | 전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물 |
| SI3152199T1 (sl) | 2014-06-03 | 2018-12-31 | Idorsia Pharmaceuticals Ltd | Pirazolne spojine in njihova uporaba kot blokatorji kalcijevega kanala tipa T |
| US10246426B2 (en) | 2014-09-15 | 2019-04-02 | Idorsia Pharmaceuticals Ltd | Triazole compounds as T-type calcium channel blockers |
| US9718789B2 (en) | 2015-01-30 | 2017-08-01 | Neurocrine Biosciences, Inc. | Substituted triazoles and methods relating thereto |
| ES2959658T3 (es) * | 2015-02-27 | 2024-02-27 | Calcimedica Inc | Tratamiento de la pancreatitis |
-
2015
- 2015-06-02 SI SI201530461T patent/SI3152199T1/sl unknown
- 2015-06-02 TW TW104117850A patent/TWI675827B/zh active
- 2015-06-02 CA CA2947002A patent/CA2947002C/en active Active
- 2015-06-02 PL PL15728640T patent/PL3152199T3/pl unknown
- 2015-06-02 RS RS20181305A patent/RS57943B1/sr unknown
- 2015-06-02 LT LTEP15728640.2T patent/LT3152199T/lt unknown
- 2015-06-02 NZ NZ727818A patent/NZ727818A/en unknown
- 2015-06-02 KR KR1020167036470A patent/KR101906031B1/ko active IP Right Grant
- 2015-06-02 MX MX2016015923A patent/MX2016015923A/es active IP Right Grant
- 2015-06-02 ES ES15728640T patent/ES2696351T3/es active Active
- 2015-06-02 AU AU2015270118A patent/AU2015270118C1/en active Active
- 2015-06-02 EP EP15728640.2A patent/EP3152199B1/en active Active
- 2015-06-02 CN CN201580028246.2A patent/CN106414429B/zh active Active
- 2015-06-02 JP JP2016571138A patent/JP6195684B2/ja active Active
- 2015-06-02 TR TR2018/16624T patent/TR201816624T4/tr unknown
- 2015-06-02 TN TN2016000542A patent/TN2016000542A1/en unknown
- 2015-06-02 PT PT15728640T patent/PT3152199T/pt unknown
- 2015-06-02 HU HUE15728640A patent/HUE040489T2/hu unknown
- 2015-06-02 DK DK15728640.2T patent/DK3152199T3/en active
- 2015-06-02 AR ARP150101743A patent/AR100712A1/es active IP Right Grant
- 2015-06-02 US US15/316,100 patent/US9932314B2/en active Active
- 2015-06-02 WO PCT/IB2015/054164 patent/WO2015186056A1/en active Application Filing
- 2015-06-02 MA MA40281A patent/MA40281B1/fr unknown
- 2015-06-02 PE PE2016002493A patent/PE20170129A1/es unknown
- 2015-06-02 SG SG11201609974PA patent/SG11201609974PA/en unknown
- 2015-06-02 EA EA201692521A patent/EA031104B1/ru not_active IP Right Cessation
- 2015-06-02 TW TW108115051A patent/TWI690513B/zh active
- 2015-06-02 UA UAA201613231A patent/UA121548C2/uk unknown
-
2016
- 2016-11-09 PH PH12016502230A patent/PH12016502230A1/en unknown
- 2016-11-29 IL IL249275A patent/IL249275B/en active IP Right Grant
- 2016-12-01 CL CL2016003092A patent/CL2016003092A1/es unknown
- 2016-12-21 ZA ZA2016/08821A patent/ZA201608821B/en unknown
-
2017
- 2017-12-19 US US15/847,611 patent/US10065929B2/en active Active
-
2018
- 2018-10-12 HR HRP20181670TT patent/HRP20181670T1/hr unknown
- 2018-11-15 CY CY181101214T patent/CY1120864T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100712A1 (es) | Compuestos de pirazol como bloqueadores de los canales de calcio tipo t | |
| AR099400A1 (es) | Compuesto heterocíclico fusionado | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR110405A1 (es) | Compuestos | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR099789A1 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
| AR095339A1 (es) | Compuestos moduladores alostericos de la hemoglobina | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina | |
| AR099646A1 (es) | Fotoestabilizantes de aminas impedidas | |
| AR100439A1 (es) | Derivados de carboxamida | |
| AR089753A1 (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7 | |
| AR102079A1 (es) | DERIVADOS BICÍCLICOS QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS b2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3 | |
| AR101255A1 (es) | Derivados de isoindolinona | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
| AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
| AR097252A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| AR101222A1 (es) | Derivados de piridona | |
| AR109950A1 (es) | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA | |
| AR101798A1 (es) | Quinolinas herbicidas | |
| AR113811A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos | |
| AR096984A1 (es) | Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona | |
| AR104539A1 (es) | Compuestos cíclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |